DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

TESARO (NASDAQ: TSRO)

28.10 0.82 (3.01%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TSRO $28.10 3.01%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $27.20
Previous Close $27.28
Daily Range $26.95 - $28.45
52-Week Range $22.15 - $41.25
Market Cap $1.0B
P/E Ratio -15.16
Dividend (Yield) $0.00 (0.0%)
Volume 231,658
Average Daily Volume 422,674
Current FY EPS -$4.71

Sector

Healthcare

Industry

Drugs

TESARO (TSRO) Description

TESARO Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. Website: http://www.tesarobio.com/

News & Commentary

What Was Behind Tesaro Inc.'s 21% Pop?

Tesaro and Opko's rolapitant successfully achieved primary and secondary endpoints in reducing chemotherapy-induced nausea and vomiting.

Benzinga's Top Initiations

Weakness Seen in Tesaro, Inc. (TSRO): Stock Tumbles 9.0% - Tale of the Tape

TESARO Announces Offering of $165 Million of Convertible Senior Notes Due 2021

TRACON Pharmaceuticals Completes $27M Financing And Expands Management Team And Board of Directors

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog

Sector Update: Health Care Stocks End Mixed; Opko Health, Tesaro Climb After Submitting New Drug Ap

Sector Update: Health Care Stocks End Mixed; Opko Health, Tesaro Climb After Submitting New Drug Application for Anti-Nausea Medication

Sector Update: Health Care

TESARO Announces Submission Of Rolapitant New Drug Application To FDA

TESARO Announces Submission Of Rolapitant New Drug Application To FDA

TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog

TESARO's' (TSRO) CEO Lonnie Moulder on Q2 2014 Results - Earnings Call Transcript

See More TSRO News...